Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZD9829 |
Synonyms | |
Therapy Description |
AZD9829 is an antibody-drug conjugate (ADC) comprising an IL3RA (CD123)-targeted antibody linked to the TOP1 inhibitor AZ14170132, which potentially induces DNA damage and apoptosis in IL3RA (CD123)-expressing cancer cells and inhibits tumor growth (Blood (2023) 142 (Supplement 1): 5957). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD9829 | AZD 9829|AZD-9829 | AZD9829 is an antibody-drug conjugate (ADC) comprising an IL3RA (CD123)-targeted antibody linked to the TOP1 inhibitor AZ14170132, which potentially induces DNA damage and apoptosis in IL3RA (CD123)-expressing cancer cells and inhibits tumor growth (Blood (2023) 142 (Supplement 1): 5957). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06179511 | Phase Ib/II | AZD9829 | Study of AZD9829 in CD123+ Hematological Malignancies | Recruiting | USA | ITA | GBR | ESP | DEU | AUS | 4 |